Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT)

Next Previous
Trial Profile

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Bicalutamide (Primary) ; Buserelin (Primary) ; Degarelix (Primary) ; Flutamide (Primary) ; Goserelin (Primary) ; Histrelin (Primary) ; Leuprorelin (Primary) ; Prednisone (Primary) ; Relugolix (Primary) ; Triptorelin (Primary)
  • Indications Adenocarcinoma; Cancer metastases; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms PREDICT-RT

Most Recent Events

  • 07 Mar 2025 Planned number of patients changed from 2478 to 2753.
  • 19 Jan 2022 Planned End Date changed from 31 Dec 2038 to 31 Dec 2033.
  • 19 Jan 2022 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top